Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fexofenadine in pollutant-aggravated seasonal allergic rhinitis
NCT03664882Phase 3Completed
- Sponsor
- Sanofi
- Start
- Sep 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fexofenadine in seasonal allergic rhinitis (SAR), sponsored by Sanofi. Started Sep 2018; status: completed.
02
Drugs
fexofenadine
03
Conditions
seasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on NCT03664882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03664882.